Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Share-based Compensation (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Share-based Compensation data on record, last reported at $21.2 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 19.26% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $104.0 million, down 8.87%, while the annual FY2025 figure was $104.0 million, 8.87% down from the prior year.
  • Share-based Compensation reached $21.2 million in Q4 2025 per APLS's latest filing, down from $28.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $30.3 million in Q1 2024 and bottomed at $16.4 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $24.3 million, with a median of $25.2 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 76.88% in 2021, then dropped 19.26% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $19.3 million in 2021, then rose by 25.52% to $24.2 million in 2022, then grew by 8.16% to $26.2 million in 2023, then grew by 0.36% to $26.3 million in 2024, then decreased by 19.26% to $21.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $21.2 million in Q4 2025, $28.2 million in Q3 2025, and $27.2 million in Q2 2025.